相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia
Kwang Kon Koh et al.
ATHEROSCLEROSIS (2011)
The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus
Marshall Elam et al.
CLINICAL LIPIDOLOGY (2011)
Comment on: American Diabetes Association. Standards of medical care in diabetes-2011 (vol 34, pg e53, 2011)
V Basevi et al.
DIABETES CARE (2011)
Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
P. L. Drury et al.
DIABETOLOGIA (2011)
Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study
T. M. E. Davis et al.
DIABETOLOGIA (2011)
Effect of Gemfibrozil and Fenofibrate on the Pharmacokinetics of Atorvastatin
Lloyd R. Whitfield et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation
Atsuko Tomizawa et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2011)
Standards of Medical Care in Diabetes-2011 AMERICAN DIABETES ASSOCIATION
DIABETES CARE (2011)
Pharmacoepidemiology Safety Study of Fibrate and Statin Concomitant Therapy
Cheryl Enger et al.
AMERICAN JOURNAL OF CARDIOLOGY (2010)
Effects of Combination Lipid Therapy in the Management of Patients With Type 2 Diabetes Mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial
Andrew M. Tonkin et al.
CIRCULATION (2010)
Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated Type 2 diabetic patients
Sandra J. Hamilton et al.
CLINICAL SCIENCE (2010)
Implications of the ACCORD Lipid study: perspective from the Residual Risk Reduction Initiative (R3i)
J. C. Fruchart et al.
CURRENT MEDICAL RESEARCH AND OPINION (2010)
Pleiotropic Effects of Atorvastatin and Fenofibrate in Metabolic Syndrome and Different Types of Pre-Diabetes
Robert Krysiak et al.
DIABETES CARE (2010)
Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
David C. Burgess et al.
EUROPEAN HEART JOURNAL (2010)
Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome
Renata Belfort et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes.
Emily Y. Chew et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus.
Lukasz Januszkiewicz
KARDIOLOGIA POLSKA (2010)
Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus
William C. Cushman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
A Novel Method to Adjust Efficacy Estimates for Uptake of Other Active Treatments in Long-Term Clinical Trials
John Simes et al.
PLOS ONE (2010)
Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances
Robert Krysiak et al.
PHARMACOLOGICAL REPORTS (2010)
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Henry N. Ginsberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Effect of Fibrates on Lipid Profiles and Cardiovascular Outcomes: A Systematic Review
Samuel Abourbih et al.
AMERICAN JOURNAL OF MEDICINE (2009)
Peroxisome proliferator-activated receptor-alpha (PPARα): At the crossroads of obesity, diabetes and cardiovascular disease
Jean-Charles Fruchart
ATHEROSCLEROSIS (2009)
Effects of Atorvastatin 10 mg and Fenofibrate 200 mg on the Low-Density Lipoprotein Profile in Dyslipidemic Patients: A 12-Week, Multicenter, Randomized, Open-Label, Parallel-Group Study
Jean-Claude Ansquer et al.
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL (2009)
Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
Russell Scott et al.
DIABETES CARE (2009)
Regulatory Effects of Fenofibrate and Atorvastatin on Lipoprotein A-I and Lipoprotein A-I:A-II Kinetics in the Metabolic Syndrome
Dick C. Chan et al.
DIABETES CARE (2009)
Advances in the Medical Treatment of Diabetic Retinopathy
Rafael Simo et al.
DIABETES CARE (2009)
Preventing diabetic complications: A primary care perspective
Paul Zimmet
DIABETES RESEARCH AND CLINICAL PRACTICE (2009)
Clinical insights from the Fenofibrate Intervention and Event Lowering in Diabetes study: a community practice perspective
P. P. Toth
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2009)
Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial
Kushwin Rajamani et al.
LANCET (2009)
Effect of Fenofibrate on Adiponectin and Inflammatory Biomarkers in Metabolic Syndrome Patients
Robert S. Rosenson
OBESITY (2009)
Fenofibrate abrogates postprandial blood viscosity among hypertriglyceridemia subjects with the metabolic syndrome
Robert S. Rosenson et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2009)
Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome
Robert S. Rosenson
AMERICAN HEART JOURNAL (2008)
Expert Perspective: Reducing Cardiovascular Risk in Metabolic Syndrome and Type 2 Diabetes Mellitus Beyond Low-Density Lipoprotein Cholesterol Lowering
Peter H. Jones
AMERICAN JOURNAL OF CARDIOLOGY (2008)
Atorvastatin and fenofibrate have comparable effects on VLDL - Apolipoprotein C-III kinetics in men with the metabolic syndrome
Dick C. Chan et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels
Wimon Phuntuwate et al.
ATHEROSCLEROSIS (2008)
Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study
T. M. E. Davis et al.
DIABETOLOGIA (2008)
Lipoprotein management in patients with cardiometabolic risk - Consensus conference report from the American diabetes association and the American college of cardiology foundation
John D. Brunzell et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
PPARα activators upregulate eNOS activity and inhibit cytokine-induced NF-κB activation through AMP-activated protein kinase activation
Toshie Okayasu et al.
LIFE SCIENCES (2008)
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing
Michel Farnier
VASCULAR HEALTH AND RISK MANAGEMENT (2008)
Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial
A. C. Keech et al.
LANCET (2007)
Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2
Vasilios G. Saougos et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus
A. Hiukka et al.
DIABETOLOGIA (2007)
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Philip Barter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome
Robert S. Rosenson et al.
DIABETES CARE (2007)
Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia
Kenji Oki et al.
ENDOCRINE JOURNAL (2007)
Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway
Jaetaek Kim et al.
EXPERIMENTAL EYE RESEARCH (2007)
Safety considerations with fibrate therapy
Michael H. Davidson et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
European guidelines on cardiovascular disease prevention in clinical practice: Executive summary
Ian Graham et al.
ATHEROSCLEROSIS (2007)
The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia - The DIACOR (Diabetes and Combined Lipid Therapy Regimen) Study
Joseph B. Muhlestein et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-α activators -: Clinical and experimental evidence
A Zambon et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate
A Tenenbaum et al.
ARCHIVES OF INTERNAL MEDICINE (2006)
Gemfibrozil in the treatment of dyslipidemia -: An 18-year mortality follow-up of the Helsinki Heart Study
L Tenkanen et al.
ARCHIVES OF INTERNAL MEDICINE (2006)
Effect of fenofibrate on the level of asymmetric dimethylarginine in individuals with hypertriglyceridemia
TL Yang et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects
LE Gustavson et al.
CLINICAL THERAPEUTICS (2006)
Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients
KK Koh et al.
DIABETES CARE (2006)
Lipid transfer proteins and apolipoprotein B-100 metabolism in the metabolic syndrome treated with fenofibrate
J. Ji et al.
ATHEROSCLEROSIS SUPPLEMENTS (2006)
Decrease in CETP activity by fenofibrate may increase LDL particle size measured by HPLC method in patients with coronary artery disease
T. Kiyanagi et al.
ATHEROSCLEROSIS SUPPLEMENTS (2006)
Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism
JC Fruchart et al.
DRUGS OF TODAY (2006)
Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions
MH Davidson
EXPERT OPINION ON DRUG SAFETY (2006)
Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome
Gerald F. Watts et al.
CLINICAL SCIENCE (2006)
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial
A Keech et al.
LANCET (2005)
Effect of fenofibrate on lipoprotein(a) in hypertriglyceridemic patients - Impact of change in triglyceride level and liver function
HS Ko et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2005)
The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3α-hydroxy isomeric metabolite
LE Gustavson et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Effects of fenofibrate on inflammatory cytokines and blood pressure in patients with hypertriglyceridemia
P Ye et al.
CLINICA CHIMICA ACTA (2005)
Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia
KK Koh et al.
DIABETES CARE (2005)
Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner
R Arakawa et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome
A Tenenbaum et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia
KK Koh et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: A comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia
A Saklamaz et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2005)
Effect of monthly atorvastatin and fenofibrate treatment on monocyte chemoattractant protein-1 release in patients with primary mixed dyslipidemia
B Okopien et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2005)
The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidaemic hypertensive patients
E Coban et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2005)
Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS)
JC Ansquer et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2005)
Regulation of human ApoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor α modulation
H Duez et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Reporting rate of Rhabdomyolysis with fenofibrate plus statin versus gemfibrozil plus any statin
PH Jones et al.
AMERICAN JOURNAL OF CARDIOLOGY (2005)
Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia
PN Durrington et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2004)
Effect of Fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes Mellitus
J Genest et al.
AMERICAN JOURNAL OF CARDIOLOGY (2004)
Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values
V Tsimihodimos et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2004)
Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide
LI Kajosaari et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans
AJ Bergman et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe
T Kosoglou et al.
CURRENT MEDICAL RESEARCH AND OPINION (2004)
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
SM Grundy et al.
CIRCULATION (2004)
Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis
KK Koh et al.
ATHEROSCLEROSIS (2004)
Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics
MR Jones et al.
CLINICAL PHARMACOKINETICS (2004)
Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL
K Winkler et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2004)
Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles
TD Wang et al.
ATHEROSCLEROSIS (2003)
Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia
HJ Milionis et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia
J Kowalski et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease - The Diabetes Atherosclerosis Intervention Study (DAIS)
J Vakkilainen et al.
CIRCULATION (2003)
Fenofibrate inhibits angiogenesis in vitro and in vivo
J Varet et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2003)
Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome
GF Watts et al.
DIABETES (2003)
Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia
WH Capell et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2003)
An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers
PD Martin et al.
CLINICAL THERAPEUTICS (2003)
Comparison of micronized fenofibrate and pravastatin in patients with primary hyperlipidemia
J Ducobu et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2003)
Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control
E Cavallero et al.
ATHEROSCLEROSIS (2003)
Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients
I Lemieux et al.
ANNALS OF MEDICINE (2003)
The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease
G Paragh et al.
DIABETES & METABOLISM (2003)
Diabetes, plasma insulin, and cardiovascular disease - Subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT)
HB Rubins et al.
ARCHIVES OF INTERNAL MEDICINE (2002)
Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus
DA Playford et al.
AMERICAN JOURNAL OF CARDIOLOGY (2002)
Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients
F Forcheron et al.
DIABETES (2002)
Effects of fenoribrate on high-density lipoprotein particle size in patients with hyperlipidemia: A randomized, double-blind, placebo-controlled, multicenter, crossover study
J Sasaki et al.
CLINICAL THERAPEUTICS (2002)
Efficacy and tolerability of a Suprabioavailable formulation of Fenofibrate in patients with dyslipidemia: A pooled analysis of two open-label trials
BR Ramjattan et al.
CLINICAL THERAPEUTICS (2002)
Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia
VG Athyros et al.
DIABETES CARE (2002)
Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels:: a 12-week randomized trial
JP Després et al.
JOURNAL OF INTERNAL MEDICINE (2002)
Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial - FAT)
J Malik et al.
CARDIOVASCULAR RESEARCH (2001)
Effects of fenofibrate and gemfibrozil on plasma homocysteine
S Westphal et al.
LANCET (2001)
Fenofibrate raises plasma homocysteine levels in the fasted and fed states
R Bissonnette et al.
ATHEROSCLEROSIS (2001)
Relation of gemfibrozil treatment and lipid levels with major coronary events - VA-HIT: A randomized controlled trial
SJ Robins et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia
DN Kiortsis et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2000)
Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X
B Idzior-Walus et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2000)
Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease - The bezafibrate infarction prevention (BIP) study
Z Schlesinger et al.
CIRCULATION (2000)
CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors
G Chinetti et al.
CIRCULATION (2000)
Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state
J Genest et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2000)
Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers
WJ Pan et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2000)
分享论文
